Clinical Trial Update: A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD) [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial evaluating Lovaza (omega-3 fatty acids) in pediatric sickle cell disease is underway; current status is not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemoglobin Beta-thalassemia
• Sickle Cell Disease

Drugs mentioned

• LOVAZA (OMEGA-3-ACID ETHYL ESTERS)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Sickle Cell Disease, HEMOGLOBIN SS | Phase 2 | Status: UNKNOWN